12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GKM-001: Phase Ib/IIa data

An Indian Phase Ib/IIa trial in 60 Type II diabetics showed that once-daily doses of 25, 50, 200, 600 and 1,000 mg GKM-001 for 14...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >